DISCO PHARMACEUTICALS
LIVE

Serial Number

79411970

Owner

DISCO Pharmaceuticals GmbH

Attorney

Christopher M. Kindel

Filing Date

Jun 13, 2024

Add to watchlist:

No watchlists yet
View on USPTO

DISCO PHARMACEUTICALS Trademark

Serial Number: 79411970

DISCO PHARMACEUTICALS is a trademark filed by DISCO Pharmaceuticals GmbH on June 13, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

DISCO Pharmaceuticals GmbH (2 trademarks)

Gottfried-Hagen-Straße 60-62

Entity Type: 98

Trademark Details

Filing Date

June 13, 2024

Registration Date

Not Registered

Goods & Services

Medical services, in particular for therapeutic and preventative treatment of tumours, infectious diseases, autoimmune disorders and allergies, for treating inherited genetic diseases and for protein and enzyme replacement therapy, and for treating neurological, neuromuscular, neurodegenerative and cardiovascular diseases, and for treating metabolic disorders

Chemical preparations for medical use, namely, for treating neurological, neuromuscular, neurodegenerative, cardiovascular diseases, infectious diseases, allergies, autoimmune disorders, tumours, metabolic disorders, and inherited genetic diseases; pharmaceutical preparations for the prevention and treatment of neurological, neuromuscular, neurodegenerative, cardiovascular diseases, infectious diseases, allergies, autoimmune disorders, tumours, metabolic disorders, and inherited genetic diseases; immunostimulatory compositions being pharmaceutical preparations for the prevention and treatment of neurological, neuromuscular, neurodegenerative, cardiovascular diseases, infectious diseases, allergies, autoimmune disorders, tumours, metabolic disorders, and inherited genetic diseases; vaccines; adjuvant immunostimulants, namely, adjuvants for medical purposes; pharmaceuticals and medicines based on biological micromolecules for treating neurological, neuromuscular, neurodegenerative, cardiovascular diseases, infectious diseases, allergies, autoimmune disorders, tumours, metabolic disorders, and inherited genetic diseases; pharmaceuticals and medicines, namely, enzymes and proteins for medical use in protein and enzyme replacement therapy; Pharmaceutical preparations for gene therapy for the treatment of neurological, neuromuscular, neurodegenerative, cardiovascular diseases, infectious diseases, allergies, autoimmune disorders, tumours, metabolic disorders, and inherited genetic diseases; all of the foregoing excluding nutritional supplements, phytotherapy preparations for medical purposes, and products for biomedical research and testing

Active chemical ingredients for use in the manufacture of pharmaceuticals for treating neurological, neuromuscular, neurodegenerative, cardiovascular diseases, infectious diseases, allergies, autoimmune disorders, tumours, metabolic disorders, and inherited genetic diseases; biomolecules, in particular biological macromolecules, namely, proteins for use in the manufacture of pharmaceuticals; all the foregoing for scientific and industrial purposes for the human pharmaceutical industry and excluding products for biomedical research and testing.

Scientific and technological services and research services, in particular for identifying and characterizing biological macromolecules, namely, biological and chemical research and analysis; development of pharmaceuticals preparations or vaccines; conducting of and scientific support for preclinical or clinical studies, namely, scientific research in the nature of conducting pre-clinical and clinical trials for others; all of the foregoing excluding products for biomedical research and testing

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jun 4, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
May 18, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
May 18, 2026 OPNR
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
May 7, 2026 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Nov 3, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Nov 3, 2025 GNSL
SUSPENSION LETTER WRITTEN
Nov 3, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 5, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 5, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 5, 2025 TROA
ATTORNEY REVIEW COMPLETED
Jun 27, 2025 ATRV
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
Jun 25, 2025 CREV
REFUSAL PROCESSED BY IB
Feb 22, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 5, 2025 RFCS
REFUSAL PROCESSED BY MPU
Feb 5, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 31, 2024 RFCR
NON-FINAL ACTION WRITTEN
Dec 30, 2024 CNRT
CORRECTION TRANSACTION RECEIVED FROM IB
Dec 21, 2024 CRCV
ASSIGNED TO EXAMINER
Dec 18, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Dec 13, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 13, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 12, 2024 REPR